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Abstract
Background: Patients with ST-elevation myocardial infarction (STEMI) not treated with primary or rescue
percutaneous coronary intervention (PCI) are at risk for recurrent ischemia, especially when viability in the infarct-
area is present. Therefore, an invasive strategy with PCI of the infarct-related coronary artery in patients with
viability would reduce the occurrence of a composite end point of death, reinfarction, or unstable angina (UA).
Methods: Patients admitted with an (sub)acute myocardial infarction, who were not treated by primary or rescue
PCI, and who were stable during the first 48 hours after the acute event, were screened for the study. Eventually,
we randomly assigned 216 patients with viability (demonstrated with low-dose dobutamine echocardiography) to
an invasive or a conservative strategy. In the invasive strategy stenting of the infarct-related coronary artery was
intended with abciximab as adjunct treatment. Seventy-five (75) patients without viability served as registry group.
The primary endpoint was the composite of death from any cause, recurrent myocardial infarction (MI) and
unstable angina at one year. As secondary endpoint the need for (repeat) revascularization procedures and anginal
status were recorded.
Results: The primary combined endpoint of death, recurrent MI and unstable angina was 7.5% (8/106) in the
invasive group and 17.3% (19/110) in the conservative group (Hazard ratio 0.42; 95% confidence interval [CI] 0.18-
0.96; p = 0.032). During follow up revascularization-procedures were performed in 6.6% (7/106) in the invasive
group and 31.8% (35/110) in the conservative group (Hazard ratio 0.18; 95% CI 0.13-0.43; p < 0.0001). A low rate of
recurrent ischemia was found in the non-viable group (5.4%) in comparison to the viable-conservative group
(14.5%). (Hazard-ratio 0.35; 95% CI 0.17-1.00; p = 0.051).
Conclusion: We demonstrated that after acute MI (treated with thrombolysis or without reperfusion therapy)
patients with viability in the infarct-area benefit from a strategy of early in-hospital stenting of the infarct-related
coronary artery. This treatment results in a long-term uneventful clinical course. The study confirmed the low risk of
recurrent ischemia in patients without viability.
Trial registration: ClinicalTrials.gov: NCT00149591.
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Background
Management of acute myocardial infarction (AMI) has
changed considerably over the last two decades [1-3].
Optimal treatment for patients who have acute myocar-
dial infarction with ST-segment elevation includes early
reperfusion with primary PCI or thrombolytic therapy.
Due to the low availability of primary PCI, most patients
with STEMI are treated with intravenous thrombolysis.
Even in developed countries many patients receive
thrombolytic therapy. Approximately one third of eligi-
ble patients do not receive early reperfusion therapy, in
many cases because of late presentation [4].
After successful thrombolysis, more than 50% of
patients have a significant residual stenosis and about
20-30% suffer from recurrent ischemic events because of
plaque-instability in the infarct-related coronary artery
[5]. Thus, after initial salvage of myocardium - being the
primary goal of thrombolytic therapy - the rescued,
viable myocardium is at risk for recurrent ischemia and
necrosis. Several studies have indeed shown that after
thrombolysis patients with residual viability in the
infarct-area are at increased risk of recurrent ischemia
or reinfarction [6-13]. Viability in the infarct zone is
thought to be a potential substrate for future cardiac
events. The impact of revascularization on clinical out-
come in patients with viability after AMI was studied in
a meta-analysis of non-randomized data [14]. Patients
with viable tissue in the infarct area experienced signifi-
cant less cardiac events after a revascularization
procedure.
In contrast, the cardiac event-rate in patients without
viability was low and did not change by an invasive
strategy. In current clinical practice, viability-testing is
not used as a tool for post-myocardial infarction risk-
assessment and patient management. We report the
results of the Viability-guided Angioplasty after acute
Myocardial Infarction (VIAMI) trial, which tested the
hypothesis that a strategy of viability guided angioplasty
with stenting after AMI in patients treated with throm-
bolysis or who were too late for reperfusion therapy and
remained stable for 48 hours, would reduce the occur-
rence of a composite end point of death, reinfarction, or
unstable angina.
Methods
Study population and study design
The methods used in the trial have been described pre-
viously [15]. In brief, the VIAMI-trial was a prospective,
multicenter, randomized, controlled clinical trial (RCT).
Between April 2001 and January 2006, 291 patients were
enrolled from 11 participating Dutch hospitals. Patients
admitted to any of the participating centers with an
(sub)acute myocardial infarction, who were not treated
by primary or rescue angioplasty, and who were stable
during the first 48 hours after the acute event, were
screened for the study.
Stable patients revealed no signs of ongoing ischemia
based on electrocardiographic characteristics or persis-
tent chest discomfort. Patients who were admitted
within 6 hours after symptom onset, received thrombo-
lysis combined with heparin. Patients admitted more
than 6 hours after symptom onset, received only heparin
or low weight molecular heparin (LWMH).
Patients < 80 years of age were considered suitable
for the study when they met the criteria for definite
myocardial infarction, i.e. an significant rise in creatine
kinase-MB levels (twice the upper limit of normal:
ULN), 1 mm ST segment elevation in two or more
standard leads or 2 mm ST segment elevation in two
contiguous chest leads, and/or the development of Q
waves.
Patients underwent low dose dobutamine echocardio-
graphy (LDDE) for the detection of viability within 72
hours after AMI. It is a safe and well-validated bedside
test with a diagnostic accuracy of about 80%, which is
comparable to scintigraphical techniques (SPECT/PET)
[16]. Before the administration of dobutamine, a base-
line echocardiogram is performed. Five standard views
are obtained: the parasternal long-axis and short-axis
view and the apical two, three- and four-chamber view.
A 16-segment model is used in which the apex is
divided in 4 segments. Segmental wall motion and thick-
ening is scored according to a 4-point scale: 1 = normal,
2 = hypokinetic, 3 = akinetic, and 4 = dyskinetic. Left
ventricular volumes and ejection fraction are measured
by use of the modified Simpson’s rule algorithm from
orthogonal apical long-axis projections. Dobutamine is
administrated intravenously at doses of 5, 10, and 15
μg/kg/min, for 5 minutes at each dose. When a 10%
increase in heart rate is not achieved with 15 μg/kg/min,
a 5-minute infusion with 20 μg/kg/min can be used as
the final stage of the procedure. This test was performed
according to the guidelines of the American Society of
Echocardiography [17].
Viability was defined as the improvement of wall
motion abnormalities (WMA’s) in two or more seg-
ments of the infarct zone. Patients without WMA’s were
not included in this trial. In case of poor acoustic win-
dow ultrasound contrast agents were used to improve
image quality and diagnostic yield.
All images were sent to the core-lab (VU University
Medical Center, Amsterdam, The Netherlands) and
were analyzed by 2 experienced observers. A third
observer was used in case of disagreement to reach con-
sensus. All eligible patients provided written informed
consent. The study complied with the Declaration of
Helsinki and all ethics committees of the participating
centers approved the protocol.
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Randomization and treatment
Patients with viability in the infarct-area were rando-
mized to an invasive or a conservative treatment strat-
egy. Permuted block randomization was performed with
a block size of ten. All patients were treated with
aspirin, beta blockers, angiotensin-converting-enzyme
inhibitors, statins as accepted by international guidelines
[1,2].
The invasive strategy patients underwent in-hospital
coronary angiography with the intention to perform PCI
with stenting of the infarct-related coronary artery
(IRA). In the conservative group an ischemia-guided
approach was adopted with stress testing before hospital
discharge. After a positive test for ischemia coronary
angiography was strongly recommended. If an interven-
tion was performed, it was considered planned and not
interpreted as an event. Patients without viability served
as a registry group also with a long-term follow-up.
Angiography and PCI was performed as soon as possi-
ble after randomization. When a significant (≥ 50%) ste-
nosis or occlusion of the infarct-related coronary artery
was found, PCI with stenting was performed when feasi-
ble. In all cases where PCI was performed, abciximab
was used according to the EPILOG protocol [18]. A
bolus of 0.25 mg per kilogram of body weight was admi-
nistered 10 to 60 minutes before balloon inflation, fol-
lowed by an infusion of 0.125 μg per kilogram per
minute (maximum, 10 μg per minute) for 12 hours.
After stenting, all patients received oral clopidogrel with
a 300 mg loading dose. In case of severe 3-vessel disease
or significant left main stem stenosis, where PCI is
judged to be a high risk, coronary artery bypass grafting
was to be considered.
End points
The primary endpoint was the composite of death from
any cause, recurrent infarction and unstable angina at 1-
year follow-up. Secondary endpoints were the need for
revascularization and the occurrence of angina pectoris
(Canadian Cardiovascular Society classification (CCS)).
A recurrent myocardial infarction was diagnosed if
there was an increase in the total creatine kinase and
MB isoenzyme activity (2 times ULN) and either a his-
tory of ischemic chest discomfort or electrocardio-
graphic changes indicative for trans mural ischemia or
necrosis. Reinfarction during hospitalization required a
decrease of cardiac enzymes, followed by a subsequent
rise to a level of 2 times ULN and 50% above a previous
measured value.
For the diagnosis of unstable angina, patients had to
be rehospitalized with ischemic chest pain or discomfort
occurring at rest or with minimal exertion. In addition,
the need for intravenous medical intervention and/or
objective evidence of myocardial ischemia was required.
Members of an independent clinical event and end
point committee, who were unaware of the treatment
assignments of the patients, adjudicated all end points.
Statistical analysis
The VIAMI-trial was conducted to investigate the differ-
ences in clinical outcome between an invasive and a
conservative strategy in patients with demonstrated via-
bility in the infarct-area. The expected event rate in the
viability positive group was estimated to be 35 percent.
To demonstrate with a power of 80% (a = 0.05, two-
sided) that PCI leads to a 50% reduction in event rate in
the invasive group compared to the conservative group,
200 patients would be needed in each group.
As a formal stopping rule for the study the following
was used: if one of the treatment strategies appeared
significantly superior at interim analysis (p ≤ 0.01), the
study would be stopped. Interim analysis was performed
each time another 100 patients were included.
Baseline descriptive data are presented as a mean ± stan-
dard deviations (SD). Differences in clinical and echocardio-
graphic variables are assessed by unpaired Student’s t-test.
Differences between proportions are assessed by chi-square
analysis; a Fisher’s exact test is used when appropriate.
Event-free survival curves are computed with the Kaplan-
Meier method, and the differences between these curves are
tested with a log-rank test. The Cox proportional hazards
regression analysis was used to estimate the treatment effect
as hazard ratio (HR) with 95% confidence intervals. Besides
the “crude” effects, adjustments were made for DM, hyper-
tension, hypercholesterolemia, current smoking, family his-
tory of CAD (model a), clinical history (angina, myocardial
infarction, PCI or CABG) and medication use at baseline
(aspirin, beta-blocker, Ca-inhibitor, statins, ACE-I and AT
II antagonist) (model b) and for all covariates (model c).
All analyses were performed on an intention-to-treat
basis. Outcome per-protocol was also evaluated, since
this would reflect the true influence of PCI on clinical
outcome. Because after randomization there was a med-
ian waiting-time of two days before a revascularization
procedure was performed inevitably some events
occurred. In the per-protocol analysis these events are
excluded from analysis, because they occurred before the
by protocol demanded intervention. To make a fair com-
parison between the two groups in the per-protocol ana-
lysis we also excluded the events in the conservative
group occurring during the first two days after randomi-
zation. All analyses were performed with the use of SPSS
software, version 16.0 (SPSS, Inc., Chigago, Illinois).
Results
Baseline characteristics
Between April 2001 and January 2006, 216 patients were
enrolled in the trial. Of these, 106 patients were
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randomly assigned to the invasive strategy and 110
patients to the conservative strategy. The pre-specified
number of patients was not achieved. This was mainly
caused by a slowing down of inclusion-rate in the sec-
ond half of the study period due to the fast introduction
of widely available primary PCI in the Netherlands (>
90%). At the start of this study, 50% of all AMI were
still being treated with thrombolysis in the Netherlands.
The baseline characteristics of the patients in the two
randomized groups were similar except for a lower pre-
valence of statin use in the group assigned to the con-
servative strategy (p = 0.02)(Table 1). The mean age was
60 years with about 80% male patients. Only 5% experi-
enced a prior myocardial infarction and about 3% a
revascularization procedure in the past. Almost half of
the study population was actively smoking. Time from
onset of symptoms, caused by the index infarction, to
randomization (inclusion) remained within 3 days. The
treatment of the index infarction in both groups was
comparable. Of the invasive patients 53% received
thrombolysis, compared to 45% of the conservative, the
difference being non-significant. The time from onset of
symptoms to the start of fibrinolytic therapy was also
comparable in both groups. Cardiac catheterization was
performed in 99% of patients in the invasive strategy
group (1 patient died before the assigned catheteriza-
tion). Of these patients, 73% received a percutaneous
intervention, 11% underwent coronary-artery bypass
Table 1 Baseline characteristics of the patients
Viable Non-viable
Invasive Conservative P- value*
Characteristic (n = 106) (n = 110) (n = 75)
Male 75% 81% 66% 0.41
Age (yrs) 60 59 64 0.52
Clinical history (%)
Angina 41% 44% 54% 0.68
Myocardial infarction 6% 4% 9% 0.53
Percutaneous coronary intervention 2% 3% 9% 1.0
Coronary- artery bypass grafting 0% 1% 1% 1.0
Risk factors (%)
Dabetes mellitus 8% 13% 12% 0.26
Hypertension 27% 28% 30% 1.0
Hypercholesterolemia 19% 14% 18% 0.36
Current sigaret smoking 45% 40% 64% 0.49
Family history of CAD 33% 31% 20% 0.77
Medications at admission (%)
Aspirin 17% 9% 14% 0.11
Beta- blocker 12% 12% 18% 1.0
Ca- inhibitor 9% 4% 8% 0.16
Statins 15% 6% 12% 0.02
ACE- inhibitor 8% 6% 15% 0.59
AT II antagonist 6% 6% 5% 1.0
Time from onset of symptoms To randomization-hr 73± 32 69± 25 78± 31 0.53
Time from onset of symptoms To thrombolysis-minutes 184± 155 200± 147 190± 112 0.65
Thrombolysis 53% 45% 47% 0.34
Anterior infarction 31% 33% 47% 0.88
Ejection Fraction (EF%) 52.7 54.7 53.5 0.32
Randomization to revascularization
mean (days) 5.6
median (days) 2
Occluded IRA (%) 19.8
Absence of collaterals (%) 63.2
Protocol PCI (%) 73
CABG (%) 11
No revascularization (%) 16
* Differences between the randomized groups are expressed with a P-value. Plus-minus values are means ± SD.
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surgery because of high risk anatomy and 16% did not
receive a revascularization procedure at all. Most of
these patients had non-significant coronary artery dis-
ease. In some patients the culprit vessel was too small
for PCI. Medical therapy at discharge was similar in
both randomized groups, except for the use of clopido-
grel, which drug was off course obligatory in patients
with a stent.
Primary endpoint
The primary endpoint (death, recurrent MI and/or UA
at one-year follow-up) occurred in 27 patients (8 in the
invasive group and 19 in the conservative group). By
intention-to-treat analysis the one-year event-free survi-
val was 92.5% percent in the invasive strategy group and
82.7% in the conservative strategy group (Hazard ratio,
0.42; 95 percent confidence interval, 0.18 to 0.96; p =
0.04)(Figure 1A and Table 2). Mortality after one-year
follow-up was 1.9% in the invasive group vs. 2.7% in the
conservative group (p = 1.0). The cumulative risk of
myocardial infarction within 12 months after randomi-
zation was comparable in both groups (1.9% in invasive
vs. 1.8% in conservative group; p = 1.0). The risk of UA
was significantly higher in the conservatively assigned
group (12.7% vs. 3.7%; p = 0.02). As depicted in table 3
the effect of our intervention was more pronounced
after adjustment for different variables (model c; Hazard
ratio 0.31; CI 0.12 to 0.78; p = 0.01). The per-protocol
analysis, which more accurately reflects the true influ-
ence of PCI on the occurrence of ischemic events,
revealed a greater difference between the two rando-
mized groups. The estimated one-year event-free survi-
val by per-protocol analysis was 95.3 percent for the
invasive strategy and 82.7 percent for the conservative
strategy (Hazard ratio, 0.26; 95 percent confidence inter-
val, 0.14 to 0.67; p = 0.003)(Figure 1B).
The Kaplan-Meier curves of the adjusted per-protocol
analysis revealed an estimated one-year event free survi-
val of 95.3 percent in the invasive group and 85.5 per-
cent in the conservative group (Hazard ratio, 0.31; 95
percent confidence interval, 0.15 to 0.81; p = 0.015)(Fig-
ure 1C).
There was no difference in event-rate between
patients who were treated with thrombolysis and
patients who did not receive reperfusion therapy. Pri-
mary endpoint events were similar in these two groups
(86.8% vs 88.2%; p = 0.78) (Figure 1D).
Secondary endpoint
Patients in the invasive group had a significantly lower
anginal class (CCS) (p = 0.021)(Table 4). After discharge
there was a highly significant difference between the
randomized groups in the need for revascularization
procedures. In the invasive group only 6.6% (7/106) of
patients underwent a new revascularization procedure
compared to 31.8% (35/110) in the conservative group
(p < 0.001)(Figure 1E). All but one procedures in the
invasive group were primary end point driven. One
revascularization occurred after proven ischemia (exer-
cise ECG). The reasons for revascularization in the con-
servative group are depicted in table 5.
There was no difference in revascularization proce-
dures performed in patients treated with thrombolysis
and in those who received no reperfusion therapy
(80.2% vs. 80.9%; p = 0.82)(Figure 1F).
Outcome in the non-viable registry group
No significant difference in the primary composite end-
point was found in the comparison between the non-
viable and the viable-conservative group (10.8% vs
17.3%; p = 0.22)(Figure 1G). In the analysis of the com-
ponents of the primary endpoint we found a non-signifi-
cant higher mortality in the non-viable group (5.3% vs.
2.7%; p = 0.44). Ischemic event-rate (recurrent MI and
unstable angina) in the non-viable group was much
lower than in the viable-conservative group (4.5% vs
14.5%; p = 0.051)(Figure 1H). Patients without viability
underwent as many revascularization procedures as
patients with viability who were treated conservatively
(27.3% vs. 24%; p = 0.73)(Table 5). No differences were
seen in revascularizations indicated by an abnormal pre-
discharge exercise test (4.5% vs. 9.3%, p = 0.23). The
need for primary endpoint driven revascularizations in
the non-viable group tended to be lower than in the
viable-conservative viable group (1.3% vs. 8.2%, p =
0.051). In the latter group revascularization procedures
were more often performed based on objective evidence
of ischemia (17.3% vs. 2.7%, p = 0.002). No difference in
anginal status (CCS) was observed (Table 5).
Discussion
The VIAMI-trial is the first RCT investigating a viabi-
lity-guided invasive approach in patients who were at
least 48 hours stable after acute MI (not treated with
primary PCI), demonstrating that only patients with
viable tissue in the infarct-area showed benefit from an
early in-hospital culprit vessel revascularization.
Viability was used as a sensitive marker of risk of
recurrent ischemia and recurrent infarction, with the
notion that recurrent ischemic events in the post-MI
period in most instances is related to re-thrombosis in
the infarct-related coronary artery, combined with resi-
dual viable tissue in the infarct-area.
Several studies evaluated early invasive intervention
after thrombolysis [19-25]. The only trials studying the
effect of a routine invasive strategy after fibrinolysis
beyond the time window of expected myocardial salvage
were the GRACIA-1 and OAT. The TRANSFER-AMI
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Figure 1 Kaplan-Meier estimates of the cumulative rate of; A. The composite primary end point of death from any cause, recurrent
infarction and unstable angina within one year (intention to treat analysis). Viable invasive vs. viable conservative strategy. B. The composite
primary end point of death from any cause, recurrent infarction and unstable angina within one year (per protocol analysis). Viable invasive vs.
viable conservative strategy. C. The composite primary end point of death from any cause, recurrent infarction and unstable angina within one
year (per protocol and adjusted for 2 days PCI delay). Viable invasive vs. viable conservative strategy. D. The composite primary end point of
death from any cause, recurrent infarction and unstable angina within one year (intention to treat analysis). Patients who were treated with
thrombolysis vs. patients who did not receive thrombolysis. E. The need for revascularization procedures after discharge and within one year.
Viable invasive vs. viable conservative strategy. F. The need for revascularization procedures after discharge and within one year. Patients who
were treated with thrombolysis vs. patients who did not receive thrombolysis. G. The primary composite endpoint (death, recurrent infarction
and unstable angina) within one year. Non-viable patients (registry) vs. viable conservative patients (randomized). H. The cumulative rate of
ischemic events (recurrent infarction and unstable angina) within one year. Non-viable patients (registry) vs. viable conservative patients
(randomized).
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and NORDISTEMI trials investigated this only in part.
In the GRACIA-1 trial a routine invasive strategy within
24 hours (mean 19.6 hours) of thrombolysis in the mod-
ern era of PCI was investigated, compared with ische-
mia-guided conservative approach [25]. During the
index hospital stay, no significant difference in hard
endpoints (death or reinfarction) between the conserva-
tive and invasive treated group was demonstrated. Only
the revascularization procedures differed significantly.
At 1 year follow-up, a significant reduction of ischemia-
related readmission to hospital and revascularization
was observed without significant differences in non-fatal
reinfarction or death. Both open and occluded arteries
were included. The OAT trial included only patients
with occluded arteries 3 to 28 days after AMI. There-
fore, the OAT trial is the only trial addressing the rou-
tine opening of an occluded artery beyond the time
window of expected myocardial salvage. The 4 year
cumulative primary event rate (death, reinfarction or
heart failure) did not differ significantly (17.2% PCI
group vs. 15.6% medical group), with a trend toward
excess reinfarction (p = 0.08) [26]. The TRANSFER-
AMI trial compared high risk AMI patients treated with
fibrinolysis and early PCI (< 6 hours) or fibrinolysis and
standard-treatment. Overall, 88,7% of the patients in the
standard group underwent coronary angiography after a
mean of 32.5 hours. Urgent or rescue catheterization
was performed within 12 hours after fibrinolysis in
34.9% of patients. After 6 months, no significant differ-
ences in incidence of death or reinfarction were demon-
strated between the routine early PCI and standard
treatment (p = 0.36) [20]. The same strategy was investi-
gated in the NORDISTEMI trial. The standard treat-
ment group underwent PCI 3 days (median) after AMI.
Overall, in 95% of this group angiography was per-
formed at a mean of 5.5 days. Urgent or rescue proce-
dures within 12 hours were performed in 33%. No
significant difference in primary endpoint was found
after 1 year follow up (composite death, reinfarction,
stroke, or new myocardial ischemia). Only composite of
death, reinfarction and stroke differed significantly (p =
0.01) [24]. Comparing these trials with the VIAMI-trial
is difficult, since we included only stable patients after
AMI, representing a selected group of more or less low
to intermediate risk. In the VIAMI trial no urgent or
rescue PCI was performed as these patients were not
included in the trial. In the conservative, non-invasive
group of the VIAMI trial routine angiography was not
recommended. Angiography was only performed in case
of recurrent ischemia or proven ischemia with stress-
testing. Overall, in the conservative group 41% (45/110)
of patients underwent coronary angiography.
With regard to the recommended treatment post-
thrombolysis, the AHA/ACC and ESC guidelines differ
diminutively. The AHA/ACC guidelines recommend
an early pharmacoinvasive strategy after thrombolysis
in high risk patients (Class IIa, level B). In non-high
risk patients such a strategy could be considered, espe-
cially if ischemic symptoms persist and failure to
reperfuse is suspected (Class IIb, level C). The ESC
guidelines and ESC guidelines for PCI recommend a
routine invasive strategy within 24 hours after success-
ful thrombolysis if available (Class IIa, level A). In
stable patients who did not receive reperfusion therapy,
angiography could be considered before discharge
(Class IIb, level C) [1,2,27]. However, only the GRA-
CIA-1 trial investigated a routine invasive strategy
beyond the time window of expected myocardial sal-
vage and demonstrated a reduction in endpoints
(death, re-infarction and ischemia driven revasculariza-
tion) after 12 months. In our opinion, insufficient for
the generalized statement that routine intervention is
warranted in patients after successful thrombolysis as
recommended by the ESC guidelines.
Table 2 Components of primary end points
Invasive
(n = 106)
Conservative
(n = 110)
p-value*
Composite 8 (7.5%) 19 (17.3%) 0.04
Mortality 2 (1.9%) 3 (2.7%) 1.0
Acute MI 2 (1.9%) 2 (1.8%) 1.0
Unstable Angina 4 (3.7%) 19 (12.7%) 0.02
* P-values calculated with Fisher-exact test.
Table 3 Hazard ratios for composite primary end point
(crude vs. adjusted models)
Hazard Ratio (95% CI) p- value*
Crude 0.42 (0.18 - 0.96) 0.04
Model a 0.43 (0.19 - 0.99) 0.05
Model b 0.33 (0.13 - 0.80) 0.02
Model c 0.31 (0.12 - 0.78) 0.01
* P-values calculated with cox proportional hazard regression analysis.
Model a; adjusted for DM, hypertension, hypercholesterolemia, current
smoking, family history of CAD, Model b; adjusted for clinical history (angina,
myocardial infarction, PCI or CABG) and medication use at baseline (aspirin,
beta-blokker, Ca-inhibitor, statins, ACE-I and AT II antagonist), Model c;
adjusted for all covariates used in model a and b
Table 4 Anginal class (CCS) in the randomized groups
Angina Invasive Conservative p- value*
(CCS) (n = 106) (n = 110)
I 87 (82.1%) 71 (64.5%) 0.021
II 13 (12.3%) 22 (20%) 0.021
III 5 (4.7%) 11 (10%) 0.021
IV 1 (0.9%) 6 (5.5%) 0.021
* P-value was calculated with chi-square test, Canadian Cardiovascular Society
(CCS) classification.
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As an unexpected finding, patients without viability
underwent as many revascularization procedures as
patients with viability who were randomized to the con-
servative strategy. Although patients without viability
had a low recurrence-rate of acute coronary syndrome,
they had similar reported CCS-class of angina compared
to the viable-conservative patients. Despite a lower rate
of spontaneous ischemic events and less proven ische-
mia during stress-testing, treating physicians decided to
refer patients for an invasive procedure quite as often in
the non-viable patient group. The explanation for this
remains speculative.
The results of the VIAMI trial suggest that routine
angioplasty in the early post-MI period in stable patients
(whether or not treated with thrombolysis) is not manda-
tory. Especially in patients were the transport time for
primary PCI is largely exceeding 90 minutes as recom-
mended by the AHA/ACC guidelines, thrombolysis
could be an interesting alternative with the VIAMI-trial
approach. Also in patients presenting too late for reperfu-
sion therapy (> 12 hours). Early viability-testing with low-
dose dobutamine echocardiography provides us with a
tool to identify high-risk patients who will have clinical
benefit from a revascularization procedure later on.
Limitations
The applicability of LDDE in daily practice is somewhat
limited because about 10-15% of patients have poor
acoustic windows. In our study this problem could par-
tially be overcome with selective use of ultrasound con-
trast agents.
The pre-specified number of patients was not
achieved. This was mainly caused by a slowing down of
inclusion-rate in the second half of the study period due
to the fast introduction of widely available primary PCI
in the Netherlands. Although the primary event-rate in
the viable-conservative group was lower than expected
(17.3%) the relative risk-reduction was higher than
expected (56.6%). This indicates an improvement over
time in the pharmacological post-MI treatment (statins,
clopidogrel, ACE-inhibitors). Also, it implicates further
improvement in the efficacy and safety-profile of revas-
cularization procedures. During the inclusion-period of
the VIAMI-trial treatment with clopidogrel was not
standard care in patients without stents. Standard treat-
ment with clopidogrel according to current guidelines
(CLARITY-TIMI 28 trial [28]) could have made the dif-
ferences less pronounced.
The data from the non-viable patient group should be
interpreted with caution, because this was a non-rando-
mized group.
Half of the randomized patients were not treated with
thrombolysis, making it a heterogeneous group. The
outcome in these two seemingly different patient
groups, however, was exactly the same. This finding
challenges the general idea that patients with ST-seg-
ment elevation MI not treated with thrombolysis have
completely different residual culprit vessel pathology
with different early and long term clinical outcome than
patients who were treated with thrombolysis. The
VIAMI-trial supports the concept that, ultimately, it is
viability that determines prognosis.
Conclusion
Patients who are stable for 48 hours after acute myocar-
dial infarction with viability in the infarct-area
Table 5 Components of secondary endpoints and reasons for revascularization (conservative and nonviable group)*
Conservative Nonviable p- value
(n = 110) (n = 75)
Angina (CCS)
I 71 (64.5%) 45 (60.0%) 0.54
II 22 (20%) 15 (20%) 0.54
III 11 (10%) 12 (16%) 0.54
IV 6 (5.5%) 3 (4.0%) 0.54
Total revascularizations 35 (31.8%) 25 (33.3%) 0.87
- Primary endpoint driven 9 (8.2%) 1 (1.3%) 0.05
- Abnormal predischarge X-ECG 5 (4.5%) 7 (9.3%) 0.23
- Stable angina with proven ischemia 10 (9.1%) 1 (1.3%) 0.03
- Miscellaneous or non-ischemic chest discomfort 11 (10.0%) 16 (21.3%) 0.02
PCI (before hospital discharge) 6 (5.5%) 7 (9.3%) 0.38
PCI (within one year) 20 (18.2%) 10 (13.3%) 0.42
CABG (before hospital discharge) 1 (1.0%) 2 (2.7%) 0.57
CABG (within one year) 8 (7.3%) 7 (9.3%) 0.78
TIMI flow culprit vessel (CAG) 2.16 2.45 0.41
* Differences between the treatment groups are expressed with a P-value. CAG = coronary angiography
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significantly benefit from an early invasive strategy.
Importantly, patients who were not treated with throm-
bolysis showed the same benefit as patients who
received thrombolytic therapy. An invasive approach in
patients with viability results in a clear reduction in
ischemic events and a long-term uneventful clinical
course. The risk of recurrent ischemia is low in patients
without viability.
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